Connection

Michael Hallek to Aged, 80 and over

Back to Details
This is a "connection" page, showing publications Michael Hallek has written about Aged, 80 and over.
Michael Hallek
Connection Strength
0.160
Aged, 80 and over
  1. CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia. 2019 05; 33(5):1161-1172.
    View in: PubMed
    Score: 0.022
  2. [Which drugs in Hemato-Oncology are Unnecessary or Inappropriate for Use in the Elderly?] Dtsch Med Wochenschr. 2018 02; 143(4):244-252.
    View in: PubMed
    Score: 0.021
  3. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol. 2017 Oct; 4(10):e475-e486.
    View in: PubMed
    Score: 0.020
  4. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017 05 11; 129(19):2702-2705.
    View in: PubMed
    Score: 0.020
  5. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016 Jan 14; 127(2):208-15.
    View in: PubMed
    Score: 0.018
  6. Providing care in isolation while awaiting SARS-CoV-2 test results: Considering differential diagnoses and avoiding anchoring bias. Medicine (Baltimore). 2021 Jul 30; 100(30):e26720.
    View in: PubMed
    Score: 0.007
  7. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol. 2019 06 01; 37(16):1391-1402.
    View in: PubMed
    Score: 0.006
  8. Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia. Br J Haematol. 2018 12; 183(5):727-735.
    View in: PubMed
    Score: 0.006
  9. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. Leuk Lymphoma. 2019 06; 60(6):1438-1446.
    View in: PubMed
    Score: 0.006
  10. Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence. Sci Rep. 2018 10 08; 8(1):14941.
    View in: PubMed
    Score: 0.006
  11. Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clin Cancer Res. 2018 09 15; 24(18):4371-4379.
    View in: PubMed
    Score: 0.005
  12. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol. 2018 07 01; 36(19):1973-1980.
    View in: PubMed
    Score: 0.005
  13. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. J Hematol Oncol. 2018 04 16; 11(1):55.
    View in: PubMed
    Score: 0.005
  14. Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group. Leukemia. 2017 10; 31(10):2251-2253.
    View in: PubMed
    Score: 0.005
  15. Rare germline variants in ATM are associated with chronic lymphocytic leukemia. Leukemia. 2017 10; 31(10):2244-2247.
    View in: PubMed
    Score: 0.005
  16. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 Aug 09; 367(6):520-31.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.